| |
|
|
|
Trillium Therapeutics Inc.  
|
|
6.65 -0.1 (-0.01%) |
06-22 16:00 |
|
Open: |
6.8 |
Pre close: |
6.75 |
Target:
|
8.18
|
|
High: |
6.9287 |
Low: |
6.3 |
Resistance:
|
7.00
8.18
|
|
Volume: |
70,633 |
Market Cap: |
88M |
Support:
|
6.01
5.40
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
6.42
 |
MACD |
MACD(12,26):
|
0.06 |
|
MA(20): |
6.18 |
Signal(12,26,9): |
-0.01 |
|
MA(100): |
6.79  |
Stochastic Oscillator |
%K(14,3):
|
75.43 |
|
MA(250): |
6.70 |
%D(3): |
64.61 |
|
Average Volume(K) |
3-Month: |
8075
|
52-Week |
High:
|
13.30 |
|
10-Days: |
14697 |
Low: |
4.15 |
|
RSI |
RSI(14):
|
57.45 |
Change(%): |
54.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-3.060 |
Return on Equity (ttm) |
242.2 |
Shares Out. (M) |
13.15 |
|
EPS Est. Current Year |
-4.130 |
Return on Assets (ttm) |
56.3 |
Shares Float (M) |
13.15 |
|
EPS Est. Next Year |
-2.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
-0.960 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
44.10 |
|
Forward EPS |
-2.917 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
170 |
|
Book Value (p.s.) |
5.860 |
EBITDA (p.s.) |
-1.235 |
P/E |
-2.17 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
1.13 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-21.12 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-8.55 |
P/CF |
-4.14 |
|
|
|
|
|
|
